Skip to main content

Table 2 Metabolites significantly associated with each anthropometric variable in the discovery and replication sets

From: Metabolic signatures of greater body size and their associations with risk of colorectal and endometrial cancers in the European Prospective Investigation into Cancer and Nutrition

N

Metabolites

Association with:

BMI

 

WC

 

WHR

 

β (95% CI)

p*

β (95% CI)

p*

β (95% CI)

p*

1

Asparagine

− 1.02 (− 1.25; − 0.79)

< .001

− 1.11 (− 1.38; − 0.84)

< .001

− 0.80 (− 1.15; − 0.45)

< .001

2

Glutamine

− 0.83 (− 1.05; − 0.60)

< .001

− 0.92 (− 1.18; − 0.65)

< .001

− 0.69 (− 1.03; − 0.35)

< .001

3

Glutamate

1.03 (0.83; 1.23)

< .001

1.08 (0.84; 1.32)

< .001

0.64 (0.33; 0.95)

< .001

4

Glycine

− 1.01 (− 1.24; − 0.79)

< .001

− 1.31 (− 1.57; − 1.04)

< .001

− 1.40 (− 1.74; − 1.05)

< .001

5

Isoleucine

1.04 (0.80; 1.27)

< .001

1.24 (0.95; 1.52)

< .001

1.03 (0.66; 1.39)

< .001

6

Serine

− 0.93 (− 1.15; − 0.71)

< .001

− 1.02 (− 1.29; − 0.76)

< .001

− 1.04 (− 1.38; − 0.69)

< .001

7

Valine

1.35 (1.12; 1.58)

< .001

1.49 (1.22; 1.77)

< .001

1.17 (0.82; 1.53)

< .001

8

LysoPC a C17:0

− 1.14 (− 1.35; − 0.92)

< .001

− 1.31 (− 1.56; − 1.05)

< .001

− 0.82 (− 1.15; − 0.48)

< .001

9

LysoPC a C18:1

−1.36 (− 1.57; − 1.16)

< .001

− 1.51 (− 1.75; − 1.27)

< .001

− 0.97 (− 1.28; − 0.65)

< .001

10

LysoPC a C18:2

− 1.47 (− 1.68; − 1.25)

< .001

− 1.59 (− 1.85; − 1.33)

< .001

− 1.00 (− 1.34; − 0.66)

< .001

11

PC aa C38:3

1.69 (1.46; 1.92)

< .001

1.85 (1.57; 2.12)

< .001

1.62 (1.27; 1.98)

< .001

12

PC aa C38:4

1.06 (0.83; 1.30)

< .001

1.26 (0.98; 1.54)

< .001

1.20 (0.84; 1.56)

< .001

13

PC aa C42:0

− 0.22 (− 0.27; − 0.17)

< .001

− 0.26 (− 0.32; − 0.20)

< .001

− 0.23 (− 0.31; − 0.15)

< .001

14

PC ae C34:3

− 1.26 (− 1.49; − 1.03)

< .001

− 1.7 (− 1.97; − 1.42)

< .001

− 1.77 (− 2.12; − 1.42)

< .001

15

PC ae C40:5

− 1.06 (− 1.29; − 0.83)

< .001

− 1.24 (− 1.51; − 0.97)

< .001

− 0.99 (− 1.34; − 0.64)

< .001

16

PC ae C42:5

− 1.13 (− 1.35; − 0.91)

< .001

− 1.34 (− 1.6; − 1.08)

< .001

− 1.14 (− 1.48; − 0.8)

< .001

17

Acylcarnitine C0

0.85 (0.61; 1.09)

< .001

0.92 (0.64; 1.21)

< .001

–

–

18

Acylcarnitine C3

0.27 (0.14; 0.41)

< .001

0.34 (0.18; 0.49)

< .001

–

–

19

Acylcarnitine C5

0.69 (0.51; 0.86)

< .001

0.63 (0.42; 0.83)

< .001

–

–

20

Leucine

1.09 (0.85; 1.33)

< .001

1.23 (0.95; 1.52)

< .001

–

–

21

Phenylalanine

0.78 (0.55; 1.01)

< .001

0.88 (0.61; 1.15)

< .001

–

–

22

Tyrosine

1.23 (0.98; 1.47)

< .001

1.22 (0.92; 1.51)

< .001

–

–

23

Kynurenine

1.10 (0.87; 1.33)

< .001

0.96 (0.68; 1.23)

< .001

–

–

24

PC aa C32:1

0.58 (0.36; 0.81)

< .001

0.46 (0.20; 0.73)

0.001

–

–

25

PC aa C34:4

0.57 (0.32; 0.81)

<. 001

0.44 (0.15; 0.73)

0.004

–

–

26

PC aa C38:0

− 0.46 (− 0.68; − 0.24)

<. 001

− 0.62 (− 0.88; − 0.36)

< .001

–

–

27

PC aa C40:2

− 0.11 (− 0.17; − 0.05)

< .001

− 0.14 (− 0.21; − 0.08)

< .001

–

–

28

PC aa C40:4

0.61 (0.36; 0.85)

< .001

0.78 (0.50; 1.07)

< .001

–

–

29

PC aa C40:6

0.73 (0.49; 0.96)

< .001

0.76 (0.49; 1.04)

< .001

–

–

30

PC aa C42:1

− 0.12 (− 0.15; − 0.09)

< .001

− 0.15 (− 0.18; − 0.11)

< .001

–

–

31

PC aa C42:2

− 0.56 (− 0.72; − 0.40)

< .001

− 0.61 (− 0.80; − 0.42)

< .001

–

–

32

PC ae C32:1

− 0.57 (− 0.78; − 0.37)

< .001

− 0.9 (− 1.14; − 0.66)

< .001

–

–

33

PC ae C34:2

− 0.92 (− 1.14; − 0.71)

< .001

− 1.24 (− 1.49; − 0.98)

< .001

–

–

34

PC ae C36:2

− 1.12 (− 1.35; − 0.90)

< .001

− 1.32 (− 1.59; − 1.05)

< .001

–

–

35

PC ae C36:3

−0.87 (− 1.10; − 0.65)

< .001

− 1.15 (− 1.42; − 0.88)

< .001

–

–

36

PC ae C38:2

− 1.05 (− 1.27; − 0.82)

< .001

− 1.19 (− 1.46; − 0.92)

< .001

–

–

37

PC ae C40:6

− 0.89 (− 1.12; − 0.65)

< .001

− 1.11 (− 1.38; − 0.83)

< .001

–

–

38

PC ae C44:4

− 1.05 (− 1.24; − 0.86)

< .001

− 1.11 (− 1.34; − 0.89)

< .001

–

–

39

SM C16:0

− 0.58 (− 0.74; − 0.42)

< .001

− 0.64 (− 0.83; − 0.45)

< .001

–

–

40

PC ae C44:6

− 0.64 (− 0.87; − 0.42)

< .001

–

–

–

–

41

SM C18:1

0.49 (0.34; 0.64)

< .001

–

–

–

–

42

Hexoses

0.65 (0.44; 0.87)

< .001

–

–

–

–

43

PC aa C32:2

–

–

0.45 (0.19; 0.72)

0.002

–

–

  1. Analysis using residuals from Z and Log transformed metabolites with fixed effect for country and sex and random effect for batches nested within study. The multivariable model included additional adjustment for height, physical activity, smoking status, education level, alcohol consumption, dietary intakes of total energy, red and processed meats, fish and shellfish, and fibre, age at blood collection and fasting status. *P value refers to FDR correction